Financial Performance - Net profit attributable to shareholders for the first nine months of 2024 was ¥78,770,148.31, representing an increase of 8.22% from ¥72,787,269.73 in the same period of 2023[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 41.45% to ¥66,268,563.72, compared to ¥46,849,820.03 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 increased by 167.22% to ¥15,114,188.73 compared to ¥5,656,133.01 in Q3 2023[5] - The company reported a net profit increase in retained earnings to ¥667,383,177.44 from ¥619,022,388.38, reflecting a growth of about 7.8%[25] - Net profit for the first nine months of 2024 was ¥77,520,084.72, representing a 6.5% increase from ¥72,912,899.77 in 2023[30] - The company reported a total comprehensive income of ¥77,518,876.23 for the first nine months of 2024, compared to ¥72,907,886.40 in the same period last year[30] - Total comprehensive income amounted to ¥39,012,440.38[32] Revenue and Costs - Operating revenue for the first nine months of 2024 was ¥468,292,733.23, a decrease of 9.91% from ¥519,796,894.08 in the same period of 2023[4] - Total operating revenue for the first nine months of 2024 was ¥468,292,733.23, a decrease of 9.9% compared to ¥519,796,894.08 in the same period of 2023[29] - Total operating costs decreased to ¥411,245,882.53, down 13.4% from ¥474,829,103.92 year-on-year[29] - Sales revenue from goods and services received cash of ¥499,687,176.68, down from ¥562,263,762.32[33] Assets and Liabilities - Total assets as of September 30, 2024, reached ¥1,886,866,228.27, an increase of 4.84% compared to ¥1,799,788,137.78 at the end of 2023[3] - The company's debt-to-asset ratio (consolidated) increased to 19.15% from 17.64% year-on-year[3] - Current liabilities rose to ¥254,736,175.41, compared to ¥194,961,411.90, marking an increase of about 30.7%[25] - Non-current liabilities decreased to ¥106,627,041.63 from ¥122,474,990.96, a decline of approximately 12.9%[25] - Total equity increased to ¥1,525,503,011.23, up from ¥1,482,351,734.92, reflecting a growth of about 2.9%[25] Cash Flow - The cash flow from operating activities for the first nine months of 2024 was ¥100,272,900.24, down 16.18% from ¥119,631,079.41 in the previous year[4] - Net cash flow from operating activities was ¥100,272,900.24, down from ¥119,631,079.41[34] - Cash inflow from operating activities totaled ¥535,015,466.31, compared to ¥631,624,849.71 in the previous period[33] - Cash outflow from operating activities was ¥434,742,566.07, a decrease from ¥511,993,770.30[33] - Cash flow from investment activities showed a net outflow of ¥186,682,991.87, improving from a net outflow of ¥232,505,497.46[34] - Cash inflow from investment activities reached ¥1,410,149,097.20, up from ¥1,161,566,817.03[34] - Cash flow from financing activities resulted in a net outflow of ¥33,603,623.14, compared to a net inflow of ¥329,081,607.02 previously[34] Shareholder Information - The total number of ordinary shares at the end of the period was 122,577,200, with 7,571 shareholders[10] - The largest shareholder, Beijing Kangruihua Tai Pharmaceutical Technology Co., Ltd., holds 34.82% of the shares, totaling 42,684,326 shares[12] - There were no changes in the number of unlimited sale shares, remaining at 78,644,874, which is 64.16% of total shares[10] Employee and Operational Information - The company reported a decrease of 9,245 core employees, bringing the total to 170,342, which is 0.14% of total shares[11] - The company engaged in daily related transactions, which were executed timely and disclosed properly[15] - The company has implemented a share repurchase plan, with announcements made under document numbers 2024-058 and 2024-090[15] - The company has not been subject to any investigations or penalties during the reporting period[15] Other Financial Metrics - Basic and diluted earnings per share for the first nine months of 2024 were both ¥0.64, compared to ¥0.69 in the same period last year[31] - Research and development expenses decreased to ¥57,186,846.22, down 18.6% from ¥70,264,892.66 in the previous year[29] - Sales expenses were reduced to ¥173,411,913.91, a decrease of 28.5% from ¥242,274,769.32 year-on-year[29] - Tax expenses increased to ¥9,334,386.58, up 81.5% from ¥5,154,457.78 in the same period of 2023[30] - Other income decreased to ¥17,523,192.75, down 33.1% from ¥26,185,043.01 year-on-year[29]
星昊医药(430017) - 2024 Q3 - 季度财报